Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5511MR)

This product GTTS-WQ5511MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5511MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6424MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ14561MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ14018MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ6871MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ15381MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ6552MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ11640MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ11187MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW